Bought some of these this morning as Instiutional interest as really boiled up over them. They have just announced a very positive deal and from what I can see theres quite a lot of news flow in the pipeline to keep this one going throughout the rest of the year. Its highly speculative but give me a Bio company that isnt.

Heres just a little historical detail about the company from the last results prelims 31/12/2004.

HIGHLIGHTS

Listing on London Stock Exchange raised 55 million
Kerraboot(R) received UK Drug Tariff Listing at a reimbursement price
of 14
Kerraboot(R) UK sales showed steady upward trend in first six months
of primary care promotion
Second safety and efficacy study for Cerepro(TM) showed mean patient
survival time increased by 80% in malignant glioma
Trinam(R) received Orphan Drug Designation in the EU
First international out-licensing deal signed with Teva Medical for
Kerraboot(R) in Israel
EG005 Phase II in lipodystrophy completed enrolment
Finnish manufacturing facility received Good Manufacturing Practice
certification (cGMP)
Named patient supplies of Vitor(TM) made available at request of
investigators for patients completing Phase III study
Cash of 47 million at 31 December 2004

POST YEAR-END EVENTS

Patent for Trinam(R) granted by European Patent Office

Dr Nigel Parker, CEO of Ark, commented:

'We made substantial progress in all aspects of our business in 2004 and
demonstrated that we are delivering on key milestones during our first year as a
publicly quoted company. Our progress to date supports our belief that we are
well placed to achieve our goal of becoming one of a successful new breed of
diversified healthcare companies servicing areas of high clinical need in
hospital and specialist medicine.'

ARKs History

Ark Therapeutics Group plc

Ark is a specialist healthcare group (the 'Group') with one marketed product and
three further lead products in late stage clinical development. Capitalising on
over ten years of research in vascular biology and gene-based medicine, Ark has
a balanced product portfolio targeted at specific unmet clinical needs within
vascular disease and cancer. These are large and growing markets, where
opportunities exist for effective new products to generate significant revenues.

Ark's products are sourced from related but largely non-dependent technologies
within the Group and have been selected to enable them to be taken through
development within the Company's own means and to benefit from Orphan Drug
Status and/or Fast Track Designation, as appropriate. This strategy has allowed
the Group to retain greater value and greater control of clinical development
timelines, and to mitigate the risks of dependency on any one particular
programme or development partner. Ark has secured patents or has patent
applications pending for all its lead products in principal pharmaceutical
markets.

Ark has its origins in businesses established in the mid-1990s by Professor John
Martin and Mr Stephen Barker of University College London and Professor Seppo
Yla-Herttuala of the AI Virtanen Institute at the University of Kuopio,
Finland, all of whom continue to play leading roles in the Company's research
and development programmes.

You can find full details of the last results here, http://www.uk-wire.com/cgi-bin/articles/200503100700205623J.html

Worth a punt I feel but as I have previously stated its high risk.

DYOR.

cheers GF.

I`m in today at 122.5. Looks good.

I'm in aswell great promise here, good summary GF and good luck all holders

Wellcome aboard Guys Im hoping that the newsflow will lead to upgrades as we go through the year. Present broker targets I feel and they more or less say so aswell do not reflect the potential of this one.

PLease remember patience is the key, overnight gains are not made in any solid company.

cheers GF.

Nice lift here this morning, didn't have to wait long ..!

Chiva

Yup moving along nicely on a rotten day over all.

cheers Gf.

Ticked up again over the lunch period.

cheers GF.

Pleased with this one GF,

Missed this last week Jimmy, I must be slipping. From the Investors Chronicle.

Tip Updates:
*Sell Cosalt (CSLT.L).
*Buy Speedy Hire (SDY.L) and Ark Therapeutics (AKT.L).
*Hold AttentiV Systems (ATN.L).
*African Diamonds (AFD.L) fairly priced.

cheers GF.

Looks ready to tick up.

cheers GF.

Thanks GF, i`m in on this one and feel very confident about it finishing blue today. All the best.....

Wellcome aboard Dandu71. Looking for a lot more capital appreciation here.

cheers GF.

All buys this morning so far.

cheers Gf.

Nice to see these moving upwards.

cheers Gf.

Play of the Week in Shares mag this morning and an RNS

Yup a BUY in shares mag and this from CityWire..................

Good news on CityWire today.............

More good news keeps Ark buoyant

Published: 14:27 Thursday 14 April 2005
Citywire tip and BrainsTrust constituent Ark Therapeutics has maintained its recent flow of good news with further positive news from a trial of a drug to help reduce side effects for HIV patients on anti-retroviral drugs.

Ark's shares (AKT) are 1.5p higher at 127p, a new high for the year, after completing an exploratory phase II study of its EG005 treatment for lipodystrophy.

Lipodystrophy is characterised by the potentially harmful build up of body fat in the central area of the body in patients on anti-retroviral treatments. This build up of a 'pot belly' increases the risk of cardiovascular disease. Ark's treatment has shown to be effective in reducing the condition during a three month study and the majority of patients have now signed up for another year of the study.

Ark now anticipates it may be able to commence a phase III study next year.

This adds to Ark's portfolio of potential products, it already has the Kerraboot leg and foot ulcer treatment product on sale and treatments for brain tumours and muscle wasting in various stages of development. Less than a month ago it also signed an agreement with German pharmaceutical giant Boehringer giving it intellectual property rights to therapies for cardiovascular ailments.

Citywire tipped Ark at 119p last week after revealing top fund managers AAA-rated Roger Whiteoak of Framlington and New Star's Jamie Allsopp had recently increased their exposure to the company. Analysts from Nomura, Numis and Credit Suisse First Boston have also recently issued buy recommendations with price targets ranging from 145p to 163p.

The share price has risen a little and is likely to continue to tick ahead as good news continues to come through during the year ahead.

Ark holds a place in the top 30 of Citywire's BrainsTrust Small Cap index of stocks most favoured by the best performing UK Smaller Companies fund managers.

cheers GF.

Featured last week in IC, hoping theres a further back up article.

cheers Gf.

A good time to buy these, profit taking going on here.

cheers GF.

Agreed GF, not at all taken back by the red this morning, profit taking and market sentiment I feel. D

Dandu71, certainly presents them not in with the chance of buying cheap.

cheers GF.

Good to see this ticking up gradually the last couple of days.